Table 2.
Vaccine efficacy estimates against mild, moderate and severe RV gastroenteritis
| Vaccine efficacya | Method | Source | ||||
|---|---|---|---|---|---|---|
|
RV1 |
Mild (RV episode without medical care) |
Moderate (GP visit) |
Severe (Hospitalization)b |
Nosocomialc |
|
|
| After first dose |
Calculated |
Calculated |
89.8% (8.9 to 99.8) |
Calculated |
(Calculated from) Published data Efficacy for mild and moderate cases after first season calculated from efficacy ratios for mild, moderate, severe during first season |
[53] |
| First season (after second dose) |
71.7% (50.4 to 83.9) |
91.8% (84.0 to 96.3) |
100% (81.8 to 100) |
|
|
|
| Second season |
50.5% (24.3 to 67.7) |
76.2% (63.0 to 85.0) |
92.2% (65.6 to 99.1) |
|
|
|
| Third-fifth season |
Calculated |
Calculated |
Calculated |
|
Efficacy during third to fifth season calculated as linear decline equal to reduction between first and second season |
|
|
RV5 |
|
|
|
|
|
|
| After first dose |
Calculated |
Calculated |
88% (65 to 97) |
Calculated |
(Calculated from) Published data Efficacy after first dose and between first and second dose for mild and moderate cases calculated from efficacy ratios for mild, moderate, severe during first season |
[57] |
| After second dose |
Calculated |
Calculated |
88% (69 to 96) |
|
|
|
| First season (after third dose) |
65.1% (54.1 to 73.5) |
72.0% (63.2 to 78.9) |
94.8% (89.4 to 97.8) |
|
(Calculated from) Published data |
[54,55] |
| Second season |
49.8% (27.0 to 65.4) |
58.5% (40.1 to 71.7) |
90.8% (76.9 to 97.1) |
|
|
|
| Third season |
Calculated |
Calculated |
100.0% (27.9 to 100) |
|
Efficacy during third season for mild and moderate cases calculated from efficacy ratios for mild, moderate, severe during second season |
[55] |
| Fourth-fifth season | Calculated | Calculated | Calculated | Efficacy during third to fifth season calculated as linear decline equal to reduction between first and second season | ||
aVaccine efficacy was assumed equal between eligible and ineligible, data were modeled as Pert distribution; befficacy against fatal RVGE was assumed equal to efficacy for severe disease; cefficacy against nosocomial infection based on severity distribution in original study data.
GE: gastroenteritis; GP: general practitioner; RV: rotavirus.